From The Straits Times · · 50s
US FDA rejects lung cancer drug from China
US FDA rejects Chinese lung cancer drug after trial shows no life extension.
In brief
US FDA rejects Chinese lung cancer drug after trial shows no life extension. US FDA rejected ivonescimab, a lung cancer drug invented by China's Akeso Biopharma, after clinical trials failed to show statistically significant life extension. Originally reported by The Straits Times.
FDA rejection
US FDA rejected ivonescimab, a lung cancer drug invented by China's Akeso Biopharma and licensed by Summit Therapeutics, after clinical trials failed to show statistically significant life extension.
Drug development setback
Summit Therapeutics disclosed the FDA's decision on Nov 15, 2026, after buying US rights from Akeso Biopharma, a Chinese drugmaker that invented the drug in its laboratories.
Market impact
The rejection weakens hopes that ivonescimab could rival Keytruda, though the drug is still being tested in other cancers such as colon, bladder and breast.
What to remember
US FDA rejected ivonescimab, a lung cancer drug invented by China's Akeso Biopharma, after clinical trials failed to show statistically significant life extension.
Read the TL;DR — this story on one card.




